LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lyell Immunopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.80+0.68 (+8.37%)
Close on Oct 19, 2026
- Market cap
- $205.60M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Lyell Immunopharma has not reported a dividend
No dividend per share appears in Lyell Immunopharma's annual filings since fiscal 2018.